Healthcare Services Group Q3 2026 Earnings: Segment Profit Up 45% as Net Income Falls 42%

Healthcare Services Group's third quarter reads badly and was good: net income fell 42.1% to $24.9 million and diluted EPS dropped to $0.36 from $0.59. But last year's quarter carried a $34.2 million Employee Retention Credit refund, and this year's carries none — excluding it, pre-tax income rose about 46%, segment profit jumped 44.9%, and segment margins expanded 2.6 and 3.6 points. Add a $93.5 million post-quarter acquisition, a raised 2027 growth outlook and fourth-quarter revenue guided at $535–$545 million, and the headline decline is the least informative number in the release.

The Headline Numbers​

Every figure below comes from the Q3 2026 Form 10-Q and the earnings release. The Beancount fence models the quarter, so the headline table that gates it is Q3.

Costs growing 8.5% against revenue growing 3.3% looks like margin collapse — until you remove the $34.2 million ERC credit sitting inside last year's costs. On that adjusted basis, last year's cost ratio was ~86.6% of revenue versus 83.2% now, a 340-basis-point improvement. The company beat its own 86%-range cost goal and landed adjusted SG&A at 10.2% of revenue (the release's deferred-compensation-adjusted figure), inside its 9.5–10.5% target band. Diluted EPS fell less than net income (−39% vs −42%) because buybacks shrank the share count 4.9% to 69.4 million shares.

Revenue Deep Dive: Both Segments Grow, Both Expand Margins​

Dietary is the quarter's hero: revenue up 3.9% with margin expanding from 5.1% to 8.7%, as bad-debt expense swung from a $3.7 million charge to a $0.8 million recovery. Environmental grew a steadier 2.6% with margin up to 13.3% on a similar $4.8 million bad-debt swing. Total segment profit of $51.7 million against $35.7 million last year is the cleanest measure of the operating quarter — the segment note explicitly excludes ERC refunds — and it grew 45%.

CEO Ted Wahl: "The organic growth inflection we planned for, and are now delivering, sets the stage for fourth quarter revenue in the range of $535 to $545 million and low double-digit top-line growth in 2027." The company raised its 2027 revenue growth outlook from mid-single-digits to low-double-digits on the same call.

The Margin Story: A 340-Point Improvement Wearing a Decline's Clothes​

Reported margins fell across the board; economically they rose. The right column tells the real story: strip the $34.2 million ERC refund from last year's pre-tax income and the comparison becomes $33.7 million versus ~$23.1 million, a 46% increase. At the guided 25% tax rate, ex-ERC net margin was ~3.7% last year versus 5.2% now.

Two genuine offsets keep this from being pure good news. Investment and other income collapsed from $11.8 million to $2.1 million — a $9.7 million headwind the release does not explain — and nine-month net income of $73.6 million (up 165% from $27.8 million) flatters a 2025 base that was depressed long before the ERC arrived.

Note what the release never claims: pricing power. Growth is "organic" and demand is "strong," but the only mention of price is boilerplate about needing "modest price increases" to perform. In a labor-cost business running 83% cost ratios, that absence is the margin story's soft underbelly.

The One Big Question: What Does $93.5 Million of NEXDINE Buy?​

On October 6 — six days after quarter-end, so none of this is in the numbers above — HCSG closed the acquisition of NEXDINE Hospitality for $93.5 million in cash. The release promises over $150 million in annual revenue "at comparable margins," which prices the deal below 0.7x sales for a business that would add roughly 8% to the revenue base. NEXDINE keeps its brand and leadership as a wholly owned subsidiary, and the strategic pitch is entry into senior living and hospitality-driven markets beyond the core nursing-home footprint.

Three falsifiable tripwires:

1. The Q4 guide. Revenue of $535–$545 million implies +12–14% sequentially — far above any organic run-rate, so it must include a partial quarter of NEXDINE plus the promised inflection. A print below $535 million means one of the two failed to show.
2. Margin parity. "Comparable margins" means Dietary-plus segment margins holding near current levels as NEXDINE consolidates. Watch Q4 segment margins, not just the revenue line.
3. The balance sheet after the deal. Quarter-end cash plus marketable securities of $204.3 million funded the $93.5 million price, leaving ~$110 million plus an untouched $300 million revolver. The company carries zero debt — if a revolver draw appears next quarter, the buyback ($56.6 million year-to-date) is competing with the acquisition for cash.

A secondary catalyst sits in receivables: the company recorded an estimated $6.1 million recovery in the Genesis Bankruptcy case after the court-approved sale, with "a substantially higher potential upper-range recovery" still contingent. Bad debt is already running as a net recovery; Genesis could extend that streak.

Tracking an $850 Million Company in Plain Text​

A services business with 83% cost ratios lives or dies on cost control, and cost control lives or dies on reconciliation — every labor dollar has to foot to the segment note. This is how we model every company. The Q3 income statement, exactly as filed (income negative, expenses positive, net income absorbed by Equity:Adjustments):

; Check: −479.604 + 399.215 + 48.452 − 2.109 + 0.318 + 8.851 + 24.877 = 0 ✓
2026-09-30 * "Healthcare Services Group, Inc." "FY2026Q3 Income Statement"
  Income:Revenue                                -479.604 MUSD  ; revenues
  Expenses:CostOfRevenue                         399.215 MUSD  ; costs of services provided
  Expenses:SellingGeneralAdministrative             48.452 MUSD  ; selling, general and administrative
  Income:OtherNet                                     -2.109 MUSD  ; investment and other income, net
  Expenses:OtherNet                                    0.318 MUSD  ; interest expense
  Expenses:IncomeTax                                  8.851 MUSD  ; income tax provision
  Equity:Adjustments                                 24.877 MUSD  ; consolidated net income offset

The one balance-sheet number that tells the narrative: treasury stock swelled $55.8 million year-to-date to $157.6 million while cash rose to $134.6 million — the buyback is funded by operating cash flow ($30.2 million this quarter alone), not by drawing down the fortress.

The Multi-Year Arc​

Five years of grinding low-single-digit revenue growth with net income oscillating between $34 and $59 million — and then a balance sheet that transformed: treasury stock quintupled from $30.2 million to $157.6 million as buybacks accelerated, while the $25 million line-of-credit balance of FY2022–FY2023 was repaid to zero and stayed there. Nine-month 2026 net income of $73.6 million already exceeds every full year in the ledger. If Q4 delivers the guided $535–$545 million, full-year revenue lands around $1.95 billion — 6% growth, matching the FY2025 pace.

The Verdict: Bull vs. Bear​

Bull Case

• Segment profit up 45% with both segments expanding margins 3+ points — the operating business is accelerating underneath the ERC noise.
• Q4 guided at $535–$545 million with 2027 growth raised to low-double-digits — management is putting numbers on the inflection.
• NEXDINE adds >$150 million of revenue (8%+) at <0.7x sales with zero debt incurred, funded from a $204 million cash pile.
• Buybacks with unangry math: $56.6 million year-to-date while cash rose — 4.9% share-count shrinkage amplifies every per-share metric.
• Bad debt running as a net $3.6 million recovery with a Genesis upside kicker still contingent.

Bear Case

• Headline net income fell 42% and the "real" growth story requires shareholders to normalize last year's $34.2 million ERC — a credit that flattered every 2025 comparison the company gladly reported at the time.
• Investment income collapsed $9.7 million year over year with no explanation — nearly 40% of the quarter's net income, from a line nobody models.
• Cost of services ran at 83.2% of revenue in a labor business with no pricing-power narrative — one wage cycle unwinds the whole margin story.
• NEXDINE is unproven inside HCSG: 8% revenue from hospitality and senior living diversifies the footprint but also the execution risk, with integration starting this quarter.
• The Q4 guide (+12–14% sequentially) must be more than half NEXDINE to foot — miss the acquisition contribution and the "inflection" halves.

Our Take: Look past the −42% to the +45%, but verify with Q4. The segment-profit surge, the bad-debt recoveries and the raised 2027 outlook describe a business inflecting — yet the investment-income hole, the ERC-adjusted comparisons and a first acquisition in a new vertical all demand confirmation. The $535–$545 million fourth quarter is the entire thesis in one number: beat it with margins intact, and this is a compounder re-rating; miss it, and Q3 was normalization arithmetic. Watch Q4 revenue and Dietary margins before anything else.